NASDAQ:PHAR

Pharming Group Competitors

$13.26
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.26
Now: $13.26
$13.26
50-Day Range
$12.44
MA: $13.33
$13.82
52-Week Range
$12.24
Now: $13.26
$21.99
Volume23 shs
Average Volume8,891 shs
Market Capitalization$845.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pharming Group (NASDAQ:PHAR) Vs. SEER, NUVB, IBRX, BCAB, IMCR, and CGEM

Should you be buying PHAR stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Pharming Group, including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), and Cullinan Oncology (CGEM).

Seer (NASDAQ:SEER) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Seer and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Pharming GroupN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Seer and Pharming Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Pharming Group0000N/A

Seer currently has a consensus price target of $68.00, suggesting a potential upside of 30.79%. Given Seer's higher possible upside, equities research analysts clearly believe Seer is more favorable than Pharming Group.

Valuation and Earnings

This table compares Seer and Pharming Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Summary

Seer beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Valuation and Earnings

This table compares Nuvation Bio and Pharming Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Profitability

This table compares Nuvation Bio and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Pharming GroupN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Nuvation Bio and Pharming Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Pharming Group0000N/A

Nuvation Bio currently has a consensus price target of $17.40, suggesting a potential upside of 74.00%. Given Nuvation Bio's higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Pharming Group.

Summary

Nuvation Bio beats Pharming Group on 2 of the 2 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares ImmunityBio and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Profitability

This table compares ImmunityBio and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Pharming GroupN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ImmunityBio and Pharming Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Pharming Group0000N/A

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 48.19%. Given ImmunityBio's higher possible upside, analysts plainly believe ImmunityBio is more favorable than Pharming Group.

Summary

ImmunityBio beats Pharming Group on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares BioAtla and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Profitability

This table compares BioAtla and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Pharming GroupN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioAtla and Pharming Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Pharming Group0000N/A

BioAtla currently has a consensus target price of $58.00, suggesting a potential upside of 22.49%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Pharming Group.

Summary

BioAtla beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Immunocore and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Profitability

This table compares Immunocore and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
Pharming GroupN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Immunocore and Pharming Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
Pharming Group0000N/A

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 53.18%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Pharming Group.

Summary

Immunocore beats Pharming Group on 2 of the 2 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Cullinan Oncology and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
Pharming GroupN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cullinan Oncology and Pharming Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
Pharming Group0000N/A

Cullinan Oncology currently has a consensus target price of $48.25, suggesting a potential upside of 49.38%. Given Cullinan Oncology's higher possible upside, analysts plainly believe Cullinan Oncology is more favorable than Pharming Group.

Earnings and Valuation

This table compares Cullinan Oncology and Pharming Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Summary

Cullinan Oncology beats Pharming Group on 2 of the 2 factors compared between the two stocks.


Pharming Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEER
Seer
1.2$51.99flat$3.17 billionN/A0.00Gap Down
Nuvation Bio logo
NUVB
Nuvation Bio
1.9$10.00flat$2.18 billionN/A0.00Analyst Report
IBRX
ImmunityBio
1.7$16.87flat$1.84 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
BioAtla logo
BCAB
BioAtla
1.5$47.35flat$1.59 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$35.47flat$1.53 billionN/A0.00Gap Down
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$32.30flat$1.41 billionN/A0.00News Coverage
Gap Down
EWTX
Cricut
0.3$29.54flat$1.41 billionN/A0.00News Coverage
KNTE
Kinnate Biopharma
1.7$31.55flat$1.37 billionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.07flat$1.33 billionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$29.12flat$1.29 billionN/A0.00Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.9$32.02flat$1.19 billionN/A0.00Gap Down
FDMT
4D Molecular Therapeutics
1.1$37.69flat$951.07 millionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
0.0$17.00flat$948.89 millionN/A0.00News Coverage
Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$27.01flat$948.02 millionN/A0.00Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$28.32flat$901.71 millionN/A0.00News Coverage
Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.50flat$885.10 millionN/A0.00Analyst Downgrade
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19flat$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
FNCH
Finch Therapeutics Group
0.3$17.18flat$809.95 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$13.22flat$568.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$17.76flat$559.32 millionN/A0.00News Coverage
Inventiva logo
IVA
Inventiva
1.4$14.44flat$557.76 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$18.93flat$475.62 millionN/A0.00News Coverage
Gap Up
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.48flat$456.41 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.13flat$432.21 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$17.85flat$406.23 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.8$9.93flat$398.37 millionN/A0.00Analyst Revision
PRTG
Portage Biotech
0.0$29.23flat$353.19 millionN/A0.00News Coverage
Gap Down
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.83flat$318.90 millionN/A-3.10
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.07flat$300.24 millionN/A-2.79Gap Down
LBPH
Longboard Pharmaceuticals
1.9$16.00flat$270.67 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.54flat$262.47 millionN/A0.00News Coverage
IPA
ImmunoPrecise Antibodies
0.0$12.28flat$234.78 millionN/A0.00News Coverage
Annovis Bio logo
ANVS
Annovis Bio
0.0$26.54flat$184.37 millionN/A0.00
GANX
Gain Therapeutics
0.0$13.98flat$158.41 millionN/A0.00News Coverage
Gap Down
VINC
Vincerx Pharma
1.0$19.06flat$156.39 millionN/A0.00Gap Down
LGVN
Longeveron
0.3$6.81flat$127.40 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.09flat$116.92 millionN/A0.00High Trading Volume
Analyst Revision
News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$4.64flat$100.92 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.66flat$61.20 millionN/A0.00Gap Down
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.62flat$56.49 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.17flat$51.40 millionN/A0.00Gap Down
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.87flat$45.59 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$4.66flat$31.74 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.86flat$24.03 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
0.0$45.90flat$21.30 millionN/A0.00High Trading Volume
News Coverage
Gap Down
VYNT
Vyant Bio
0.0$4.02flat$16.42 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$5.21flat$4.02 millionN/A0.00High Trading Volume
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78flat$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94flat$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08flat$0.00N/A0.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.